Shares Outstanding (Quarterly) Chart

Historical Shares Outstanding (Quarterly) Data

View and export this data back to 2012. Start Trial.
Date Value
June 30, 2026 98.30M
March 31, 2026 98.00M
December 31, 2025 96.40M
September 30, 2025 96.27M
June 30, 2025 96.18M
March 31, 2025 93.74M
December 31, 2024 92.41M
September 30, 2024 92.24M
June 30, 2024 92.07M
March 31, 2024 83.09M
December 31, 2023 82.31M
September 30, 2023 72.17M
June 30, 2023 71.47M
March 31, 2023 70.66M
December 31, 2022 70.20M
September 30, 2022 70.08M
June 30, 2022 70.01M
March 31, 2022 69.80M
December 31, 2021 69.34M
September 30, 2021 67.96M
June 30, 2021 67.76M
March 31, 2021 67.44M
December 31, 2020 66.82M
September 30, 2020 60.82M
June 30, 2020 60.41M
Date Value
March 31, 2020 59.49M
December 31, 2019 57.84M
September 30, 2019 57.75M
June 30, 2019 57.67M
March 31, 2019 57.30M
December 31, 2018 50.86M
September 30, 2018 50.53M
June 30, 2018 50.12M
March 31, 2018 49.67M
December 31, 2017 44.17M
September 30, 2017 42.49M
June 30, 2017 42.43M
March 31, 2017 42.27M
December 31, 2016 41.24M
September 30, 2016 40.05M
June 30, 2016 39.05M
March 31, 2016 38.99M
December 31, 2015 38.88M
September 30, 2015 38.82M
June 30, 2015 36.07M
March 31, 2015 38.14M
December 31, 2014 31.93M
September 30, 2014 35.30M
June 30, 2014 30.06M
March 31, 2014 30.05M

Shares Outstanding Definition

The volume of stock shares issued by the company and in the hands of the public. This number entails how much is being traded in the open market. A decreasing shares outstanding over time may be the result of company buybacks. Companies frequently make stock buybacks and retire those buybacks as treasury stock.

Read full definition.

Shares Outstanding (Quarterly) Range, Past 5 Years

View Shares Outstanding (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shares Outstanding (Quarterly) Benchmarks

View Shares Outstanding (Quarterly) Benchmarks
Start Trial
Ionis Pharmaceuticals, Inc. 165.64M
AbbVie, Inc. 1.767B
Krystal Biotech, Inc. 29.60M
BridgeBio Pharma, Inc. 196.00M
Alnylam Pharmaceuticals, Inc. 133.88M